Key result
Elevated preoperative CRP and NLR linked to worse survival in localized extremity myxofibrosarcoma.
Why the study?
To verify whether preoperative systemic inflammatory markers (CRP and NLR) can predict disease-specific survival and local recurrence rate in adults with localized extremity myxofibrosarcoma.
Do preoperative systemic inflammatory markers (CRP and NLR) predict disease-specific survival and local recurrence in adult patients with localized myxofibrosarcoma of the extremities?
Cohort (n=126)
Do preoperative systemic inflammatory markers (CRP and NLR) predict disease-specific survival and local recurrence in adult patients with localized myxofibrosarcoma of the extremities?
High preoperative CRP and NLR are associated with worse disease-specific survival in patients with localized myxofibrosarcoma of the extremities.
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: The aim of this retrospective study is to verify whether preoperative systemic inflammatory markers (serum C-reactive protein [CRP] and neutrophil-lymphocyte ratio [NLR]) can help in predicting the disease-specific survival (DSS) and local recurrence (LR) rate in adult patients affected by localized myxofibrosarcoma (MFS) of the extremities. METHODS: We reviewed 126 adult patients with primary, localized MFS of the limbs. We analyzed DSS and LR. RESULTS: Median age at the time of surgery was 68 years (range 19-92). Median CRP was 0.4 mg/dL and median NLR was 2.8. A worse DSS was found in patients who had preoperative CRP >0.5 mg/dL (p = 0.002) and in those with NLR >3.5 (p < 0.001). In multivariate analysis, tumor size and grade as well as preoperative CRP values and NLR were confirmed to be prognostic factors in terms of DSS. An increased risk of LR was found in multivariate analysis in patients with a tail sign and with high gadolinium enhancement at preoperative MRI. CONCLUSIONS: Patients with high preoperative CRP and NLR levels, as well as large and high-grade tumors, might be considered as candidates for additional, more aggressive treatment approaches or more stringent follow-up schedules.
Answers are grounded in this paper and cite their sources.
May support risk stratification in localized myxofibrosarcoma; hypothesis-generating and requires prospective validation.
No takes yet. Share an insight, caveat, or question.
Sambri et al. (2020) conducted a cohort in Primary, localized myxofibrosarcoma (MFS) of the extremities (n=126). Preoperative systemic inflammatory markers (serum CRP and NLR) was evaluated on Disease-specific survival (DSS) (p=0.002). Preoperative CRP >0.5 mg/dL (p=0.002) and NLR >3.5 (p<0.001) were significantly associated with worse disease-specific survival in patients with localized myxofibrosarcoma of the extremities.
Synapse has enriched 10 related papers. Consider them for comparative context: